JSJeffrey A. Switzer

Jeffrey A. Switzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey A. Switzer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • David C. Hess

    From the Departments of Neurology (J.S., A.B., F.N., D.H.), Neurosurgery (D.H.), Hematology/Oncology (K.N.), and Biostatistics (J.W.), Georgia Health Sciences University, Augusta, GA; College of Pharmacy, University of Georgia, Athens, GA

    2 shared publications
  • Fenwick T. Nichols

    From the Departments of Neurology (J.S., A.B., F.N., D.H.), Neurosurgery (D.H.), Hematology/Oncology (K.N.), and Biostatistics (J.W.), Georgia Health Sciences University, Augusta, GA; College of Pharmacy, University of Georgia, Athens, GA

    2 shared publications
  • Susan C. Fagan

    From the Departments of Neurology (J.S., A.B., F.N., D.H.), Neurosurgery (D.H.), Hematology/Oncology (K.N.), and Biostatistics (J.W.), Georgia Health Sciences University, Augusta, GA; College of Pharmacy, University of Georgia, Athens, GA

    2 shared publications
  • Abiodun Akinwuntan

    From the Departments of Neurology (J.A.S., A.A., F.T.N., D.C.H., A.B.), Physical Therapy (A.A.), and Biostatistics (J.W.), Georgia Health Sciences University, Augusta, GA

    1 shared publication
  • Adviye Ergul

    From the Departments of Neurology, Physiology and Biostatistics (J.A.S., D.C.H., A.E., J.L.W., V.P.-D.), Georgia Health Sciences University, Augusta, GA; the Department of Neurology (L.C.P.), University of Kentucky, Lexington, KY; the Department of Neurology, Oregon Health and Sciences University (W.M.C.), Portland, OR; and the College of Pharmacy (L.M., S.C.F.), University of Georgia, GA

    1 shared publication
  • Askiel Bruno

    From the Departments of Neurology (J.S., A.B., F.N., D.H.), Neurosurgery (D.H.), Hematology/Oncology (K.N.), and Biostatistics (J.W.), Georgia Health Sciences University, Augusta, GA; College of Pharmacy, University of Georgia, Athens, GA

    1 shared publication

Latest Publications

  • Clinical Experience With Three-Factor Prothrombin Complex Concentrate to Reverse Warfarin Anticoagulation in Intracranial Hemorrhage

    by Jeffrey A. Switzer, Jody Rocker, Phillip Mohorn, Jennifer L. Waller, Douglas Hughes, Askiel Bruno, Fenwick T. Nichols, David C. Hess, Kavita Natarajan, Susan C. Fagan

    Background and Purpose— The effectiveness of prothrombin complex concentrate (PCC) products available in the United States that contain low levels of factor VII (3-factor PCC) has not been tested. The purpose of this study was to review our experience with 3-factor PCC (Profilnine) in the setting of warfarin-associated intracranial hemorrhage (wICH). Methods— In November 2007, we implemented a protocol for reversal of anticoagulation in wICH using Profilnine. Additional treatment with fresh-frozen plasma was at the discretion of the treating physician. Medical records of all patients receiving PCC for wICH between November 1, 2007, and December 7, 2011 were reviewed. Correction of the international normalized rate (INR) was defined as an INR <1.4. Results— Seventy wICH patients were treated with Profilnine, including 46 (66%) with intraparenchymal hemorrhage, 22 (31%) with subdural hemorrhage, and 2 (3%) with subarachnoid hemorrhage. Mean INR was reduced from 3.36 to 1.96, and in 44 (62.9%) patients the INR corrected to <1.4. Baseline INR ≥3.0 decreased the likelihood of INR correction. Concomitant administration of fresh-frozen plasma (mean, 2.6 U) did not increase the likelihood of INR correction. Seven (10%) patients had serious adverse events during their hospital course, including 2 sudden deaths from suspected pulmonary embolism. Conclusions— Reversal of coagulopathy in wICH with Profilnine was incomplete and associated with serious adverse events. In the absence of available 4-factor PCC, options for urgent reversal of anticoagulation in wICH remain limited.


  • Impact of Primary Stroke Center Certification on Location of Acute Ischemic Stroke Care in Georgia

    by Jeffrey A. Switzer, Abiodun Akinwuntan, Jennifer Waller, Fenwick T. Nichols, David C. Hess, Askiel Bruno

    Background and Purpose—: Primary stroke centers (PSCs) are associated with greater rates of tissue plasminogen activator use and improved outcomes. The American Stroke Association has advocated for the preferential transport of stroke patients to PSCs. We investigated the impact of PSC certification on hospital stroke discharge patterns in Georgia communities with a choice between PSC and non-PSC. Methods—: We analyzed data from the Georgia Discharge Data System before (2004) and after stroke certification (2009). Only Metropolitan Statistical Areas containing ≥1 PSC and ≥1 non-PSC were included in the analysis. We calculated the odds of acute stroke discharge from a PSC in 2009 compared with 2004. Results—: In Georgia Metropolitan Statistical Areas with at least 1 PSC and 1 non-PSC hospital, the percent of patients discharged from a subsequently designated PSC increased from 50.2% to 56.6% between 2004 and 2009 (OR, 1.29; P <0.0001). In 4 Metropolitan Statistical Areas, the proportion of stroke discharges from PSCs increased, whereas in 2 Metropolitan Statistical Areas, there was no significant increase, and in 1, there was a trend toward less stroke discharges from PSCs. Conclusions—: Although there has been an overall increase in stroke discharges from PSCs, the impact of stroke certification on patient destination was small and inconsistent across the state suggesting that local factors influence the location of hospitalization.


  • Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke

    by Jeffrey A. Switzer, David C. Hess, Adviye Ergul, Jennifer L. Waller, Livia S. Machado, Vera Portik-Dobos, L. Creed Pettigrew, Wayne M. Clark, Susan C. Fagan

    Background and Purpose—: Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods—: The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results—: Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P =0.0022; non-tPA, P =0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P P =0.0019). Conclusions—: Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.